Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1 8Phase 3 6Phase 1/2 4Phase 2/3 3

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Non-Small-Cell Lung 13Triple Negative Breast Neoplasms 7Breast Neoplasms 6Lung Neoplasms 5Ovarian Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Endometrial Neoplasms 3Carcinoma, Ovarian Epithelial 3Neoplasms 2Medulloblastoma 2Fallopian Tube Neoplasms 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Urethral Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Thymic epithelial tumor 1Thrombocythemia, Essential 1Stage IIIB or IV Non-Small Cell Lung Cancer 1Squamous NSCLC 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Retinoblastoma 1Recurrence 1Primary Myelofibrosis 1Primary Malignant Neoplasm of Ovary 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Gemcitabine 6Carboplatin 3valrubicin 2Cisplatin 2vinflunine 1toripalimab 1pertuzumab 1disitamab vedotin 1cabazitaxel 1apaziquone 1XRP6258 1Watchful Waiting 1Vinblastine 1Trastuzumab 1Transurethral Resection of Bladder 1Tranexamic Acid 1Saline Solution 1RC48 antibody 1Oncolytic Virotherapy 1Mitomycin 1Methotrexate 1Magnetic Resonance Spectroscopy 1Lapatinib 1Interferons 1Interferon-alpha 1Gabapentin 1Circulating Tumor DNA 1Celecoxib 1BCG Vaccine 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Urinary Bladder Neoplasms × Carboplatin × Clear all
NCT07129993 2026-05-14

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Daiichi Sankyo

Phase 2/3 Recruiting
630 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07106762 2026-05-12

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Bristol-Myers Squibb

Phase 2/3 Recruiting
470 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT00014274 2013-06-12

Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2/3 Completed
238 enrolled
Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡